Latest metastatic melanoma Stories
Analyses of PROCLAIM Patient Registry Data Suggest a Therapy-Enhancing Role with Checkpoint Inhibitors for Patients with mM, and Relevant First-Line Option for Patients with mRCC SAN DIEGO,
RadioMedix, Inc., a Houston-based biotechnology company and Viewpoint Molecular Targeting LLC of Iowa City were awarded a grant by the Small Business Innovation Research (SBIR) program from the
Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/
CALGARY, April 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
DURHAM, N.C. and ALISO VIEJO, Calif., Jan. 28, 2014 /PRNewswire/ -- bioMerieux, Inc.
Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy.
- A young chicken: also used as a pet name for children.